澳门2138cn太阳娱乐网站官网-在线登录

Nanomedicine is a rapidly emerging interdisciplinary area with many challenges, especially in the area of scientific communication. Effective verbal and written scientific communication is the basis of any advancement in technology, and it has even more importance for a field, which is being developed internationally.
Nowadays, we are generating knowledge faster than ever before. The information revolution and computers are changing the way scientific information is shared and evaluated. Science publishing is also undergoing dynamic changes from printing to online, and new business models, like open access and hybrid models are on the rise. The essential question is the same for authors and publishers: is it possible to determine the value of research (manuscript or publication) before and after making it public, and if the answer is yes, what are the best, objective methods to do that?

Getting published is crucial for academicians, researchers, and students. Hiring decisions are often made on the basis of publications therefore it is necessary to understand the mechanism, and find the best publication forum for maximum exposure.

In this talk, the speaker will explain how publishing works today, what is the difference between the fundamental business models, and will summarize major changes in science publications. He will describe the use and limits of citation based metrics and ranking, and explain current scientific methods to determine ranking of journals and magazines. You will learn how to select your target audience, and which tools can be used to evaluate publication activities of journals, individuals, institutions, and countries. Dr. Balogh will introduce the Nanomedicine NBM journal, its requirements, and procedures, and will compare it to leading nanomedicine journals. A guide how to get published in Nanomedicine NBM will also be presented with a question-and-answer opportunity.

报告人简介

Dr. Lajos (Lou) Balogh is the Editor-in-Chief of the journal Nanomedicine: Nanotechnology, Biology and Medicine (Elsevier), (2013 Impact Factor=5.98, 5-year IF=7.01).

Dr. Balogh is Adjunct Professor of Pharmaceutical Sciences at Northeastern University, Boston, MA, and Professor of the Chinese Academy of Sciences for Distinguished International Scientists. He authored or coauthored over 150 scientific publications (with over 5000 citations), six book chapters, delivered more than 200 invited presentations been and awarded 12 patents in various disciplines including chemistry, chemical technology, nanotechnology and nanomedicine.

Dr. Balogh received his Ph.D. from the Kossuth L. University in Hungary in Chemical Technology and later was invited to the University of Massachusetts Lowell as a Visiting Professor in 1991. He then worked at the Michigan Molecular Institute, Midland, MI as a senior scientist, and had faculty appointments (Department of Internal Medicine, Department of Biomedical Engineering and Macromolecular Science and Engineering) at the University of Michigan, Ann Arbor, MI. Before starting his own consulting business, he was the Co-Director of the NanoBiotechnology Center and Director of Nanotechnology Research in the Department of Radiation Medicine at the Roswell Park Cancer Institute, Buffalo, NY, and at the University at Buffalo, SUNY.

He is Owner and Chief Scientific Advisor at the business AA Nanomedicine & Nanotechnology Consultants, North Andover, MA that provides scientific evaluation, feasibility studies, and concept assessments for nanomedicine related research applications, R&D projects, business plans and investments, as well as expert evaluation and technology due diligence for private companies, government agencies (NIH, NSF, DoD, USEPA, Chinese Academy of Sciences, etc.) and private investors in nanomedicine, nanobiotechnology, and nanotechnology since 2000.

Lou is member of the Nanobusiness Alliance, USA, and he serves on numerous USA, European, and International expert committees including the Steering Committee of the American National Standard Institute Nanotechnology Panel and the US Technical Advisory Committee to the International Standard Organization on Nanotechnology (TC-229).

Lou is one of the five Founders of the American Society for Nanomedicine (http://www.amsocnanomed.org)

报告二

题目：Microparticles: a road to antitumor immunity

报告人：黄波教授（杰青）

时间：11月14日（周五）下午2:40 - 3:20

报告内容摘要

Tumor cells are capable of changing their cytoskeletal structure and resulting in plasma membranes encapsulating cytosolic elements and expelling them or downloading them into the extracellular space. These specialized subcellular vesicles are called microparticles (MPs) and come in different sizes of 100 to 1000 nm in diameter. In line with the cellular components, MPs may contain numerous tumor messenger molecules, enzymes, RNAs and even DNA. This study explored the possibility of translating tumor information into antitumor immunity through the MP pathway.

Despite the critical role of dendritic cells in antitumor immune responses by cross-presenting tumor antigens to tumor-specific T cells, we found that DCs were vulnerable to take up apoptotic tumor cells but strongly captured tumor cell-derived MPs. As a result, DCs upregulated CD80, CD86 and MHC class II, concomitant with the activation of JNK, ERK and NF-kB, leading to activating tumor specific T cells. Vaccination of murine H22 hepatocarcinoma tumor cell-derived MPs prevented H22 tumor rather than MCA26 colon cancer or B16 melanoma formation in mice in a CD8 T cell dependent manner. Consistently, B16 cell-derived MPs selectively affected B16 melanoma, suggesting that tumor cell-derived MPs are tumor antigen specific. Undoubtedly, tumor cells are the roots of antitumor immune responses, however previous tumor cell-based vaccines only generated limited progress. The present study probably discloses tumor cell-derived MPs as a new generation of vaccine, leading to effective antitumor consequence.

报告人简介

Bo Huang, Ph.D., M.D.

Education and Appointment

1988-1993     M.D. Hubei Medical University, Wuhan
1996-2002    Ph.D of Biochemistry & Molecular Biology, Tongji Medical College, Huazhong University of Science & Technology, Wuhan
2002-2006     Postdoc, Karolinska Iinstitutet (Sweden), University of Calgary (Canada), and Mount Sinai School of Medicine (USA)
2006- 2012    Associate Professor & Professor, Department of Biochemistry and Molecular Biology, Tongji Medical College, Wuhan
2012.3-        Professor & vice Director of Department of Immunology, Chinese Academy of Medical Sciences, Beijing

Specialty and Research Field of Interest
1. Tumor immunology; 2. Microparticles in tumor and immunology; 3. Metabolism in tumor and immunology；4. Mechanical signaling in tumor and immunology

Selected Recent Publications
1．Ma R, Zhang W, Tang K, Zhang H, Zhang Y, Li D, Li Y, Xu P, Luo S, Cai W, Ji T, Ye D, Huang B. Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma. Nat Commun. 2013;4:2508.
2．Ma J, Cai W, Zhang Y, Huang C, Zhang H, Liu J, Tang K, Xu P, Katirai F, Zhang J, He W, Ye D, Shen GX, Huang B. Innate Immune Cell-Derived Microparticles Facilitate Hepatocarcinoma Metastasis by Transferring Integrin αMβ2 to Tumor Cells. J Immunol. 2013;191:3453-61.
3．Tang K, Zhang Y, Zhang H, Xu P, Liu J, Ma J, Lv M, Li D, Katirai F, Shen GX, Zhang G, Feng Z, Ye D, Huang B. Delivery of chemotherapeutic drugs in tumor cell-derived microparticles. Nat Commun. 2012;3:1282.
4．Liu J, Tan Y, Zhang H, Zhang Y, Xu P, Chen J, Poh YC, Tang K, Wang N, Huang B. Soft fibrin gels promote selection and growth of tumorigenic cells. Nat Mater. 2012;11:734-41.
5．Lv M, Zhang X, Jia H, Li D, Zhang B, Zhang H, Hong M, Jiang T, Jiang Q, Huang X, Huang B. An oncogenic role of miR-142-3p in human T cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor alpha and cAMP/PKA pathways. Leukemia. 2012;26:769-77.
6．Liu J, Zhang Y, Zhao J, Yang Z, Li D, Katirai F, Huang B. Mast cell: insight into remodeling a tumor microenvironment. Cancer Metastasis Rev. 2011;30:177-84.
7．Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res. 2010;70:4850-8.